Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Exquisite Sensitivity to Dual BRG1/BRM ATPase Inhibitors Reveals Broad SWI/SNF Dependencies in Acute Myeloid Leukemia.
Rago F, Rodrigues LU, Bonney M, Sprouffske K, Kurth E, Elliott G, Ambrose J, Aspesi P, Oborski J, Chen JT, McDonald ER, Mapa FA, Ruddy DA, Kauffmann A, Abrams T, Bhang HC, Jagani Z. Rago F, et al. Among authors: rodrigues lu. Mol Cancer Res. 2022 Mar 1;20(3):361-372. doi: 10.1158/1541-7786.MCR-21-0390. Mol Cancer Res. 2022. PMID: 34799403
Evaluation of two in vitro assays for tumorigenicity assessment of CRISPR-Cas9 genome-edited cells.
Lemmens M, Fischer B, Zogg M, Rodrigues L, Kerr G, Del Rio-Espinola A, Schaeffer F, Maddalo D, Dubost V, Piaia A, Mueller A, Plappert-Helbig U, Naumann U, Haegele J, Odermatt A, Martus HJ, Libertini S. Lemmens M, et al. Mol Ther Methods Clin Dev. 2021 Sep 10;23:241-253. doi: 10.1016/j.omtm.2021.09.004. eCollection 2021 Dec 10. Mol Ther Methods Clin Dev. 2021. PMID: 34703845 Free PMC article.
Allosteric Mutant IDH1 Inhibitors Reveal Mechanisms for IDH1 Mutant and Isoform Selectivity.
Xie X, Baird D, Bowen K, Capka V, Chen J, Chenail G, Cho Y, Dooley J, Farsidjani A, Fortin P, Kohls D, Kulathila R, Lin F, McKay D, Rodrigues L, Sage D, Touré BB, van der Plas S, Wright K, Xu M, Yin H, Levell J, Pagliarini RA. Xie X, et al. Structure. 2017 Mar 7;25(3):506-513. doi: 10.1016/j.str.2016.12.017. Epub 2017 Jan 26. Structure. 2017. PMID: 28132785 Free article.
MAP3K7 Loss Drives Enhanced Androgen Signaling and Independently Confers Risk of Recurrence in Prostate Cancer with Joint Loss of CHD1.
Jillson LK, Rider LC, Rodrigues LU, Romero L, Karimpour-Fard A, Nieto C, Gillette C, Torkko K, Danis E, Smith EE, Nolley R, Peehl DM, Lucia MS, Costello JC, Cramer SD. Jillson LK, et al. Among authors: rodrigues lu. Mol Cancer Res. 2021 Jul;19(7):1123-1136. doi: 10.1158/1541-7786.MCR-20-0913. Epub 2021 Apr 12. Mol Cancer Res. 2021. PMID: 33846123 Free PMC article.
Effects of Heart Rate Reduction With Either Pyridostigmine or Ivabradine in Patients With Heart Failure: A Randomized, Double-Blind Study.
Villacorta AS, Villacorta H, Caldas JA, Precht BC, Porto PB, Rodrigues LU, Neves M, Xavier AR, Kanaan S, Mesquita CT, da Nóbrega ACL. Villacorta AS, et al. Among authors: rodrigues lu. J Cardiovasc Pharmacol Ther. 2019 Mar;24(2):139-145. doi: 10.1177/1074248418799364. Epub 2018 Sep 9. J Cardiovasc Pharmacol Ther. 2019. PMID: 30198318 Clinical Trial.
Coordinate loss of MAP3K7 and CHD1 promotes aggressive prostate cancer.
Rodrigues LU, Rider L, Nieto C, Romero L, Karimpour-Fard A, Loda M, Lucia MS, Wu M, Shi L, Cimic A, Sirintrapun SJ, Nolley R, Pac C, Chen H, Peehl DM, Xu J, Liu W, Costello JC, Cramer SD. Rodrigues LU, et al. Cancer Res. 2015 Mar 15;75(6):1021-34. doi: 10.1158/0008-5472.CAN-14-1596. Cancer Res. 2015. PMID: 25770290 Free PMC article.
Lipid catabolism via CPT1 as a therapeutic target for prostate cancer.
Schlaepfer IR, Rider L, Rodrigues LU, Gijón MA, Pac CT, Romero L, Cimic A, Sirintrapun SJ, Glodé LM, Eckel RH, Cramer SD. Schlaepfer IR, et al. Among authors: rodrigues lu. Mol Cancer Ther. 2014 Oct;13(10):2361-71. doi: 10.1158/1535-7163.MCT-14-0183. Epub 2014 Aug 13. Mol Cancer Ther. 2014. PMID: 25122071 Free PMC article.